Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
See Jie YowImmunology Translational Research Programme, Life Sciences Institute, National University of Singapore, Singapore 117456, Singapore.ORCID 0000-0003-0428-5050
Bing-Chen WuImmunology Translational Research Programme, Life Sciences Institute, National University of Singapore, Singapore 117456, Singapore.ORCID 0009-0008-9395-0916
Hai Shin PungImmunology Translational Research Programme, Life Sciences Institute, National University of Singapore, Singapore 117456, Singapore.ORCID 0000-0002-6882-4861
Safwah Nasuha RosliImmunology Translational Research Programme, Life Sciences Institute, National University of Singapore, Singapore 117456, Singapore.ORCID 0009-0007-6773-0293
Hui Wen YeapImmunology Translational Research Programme, Life Sciences Institute, National University of Singapore, Singapore 117456, Singapore.ORCID 0009-0004-0182-6397
Ghin Ray GohImmunology Translational Research Programme, Life Sciences Institute, National University of Singapore, Singapore 117456, Singapore.ORCID 0009-0007-2204-1582
Kay En LowElectron Microscopy Unit, Microscopy Cluster, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0009-0003-4580-4352
Isabelle BonneDepartment of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0002-8261-6794
Jizhong ShiTransgenic and Gene Targeting Facility, Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Shuizhou YuTransgenic and Gene Targeting Facility, Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Motomi OsatoTransgenic and Gene Targeting Facility, Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.ORCID 0000-0003-3982-9054
Davey KneafseyYork Biomedical Research Institute and Department of Biology, University of York, York, UK.ORCID 0009-0005-6770-9668
Gabrielle ChappellThe Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
Ye Chean TehSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.ORCID 0000-0003-0155-2109
Shu Zhen ChongDepartment of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Melissa S F NgSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.ORCID 0000-0003-3826-2746
Immanuel KwokSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Jelena S BezbradicaThe Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.ORCID 0000-0003-1441-1727
Dave BoucherYork Biomedical Research Institute and Department of Biology, University of York, York, UK.ORCID 0000-0003-0075-8893
Kaiwen W ChenImmunology Translational Research Programme, Life Sciences Institute, National University of Singapore, Singapore 117456, Singapore.ORCID 0000-0001-5903-3251
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Inflammasomes are cytosolic multiprotein complexes that activate caspase-1, which promotes inflammation and host defense by driving cytokine maturation and pyroptosis. Several studies reported that caspase-1 selectively drives cytokine maturation without concomitant pyroptosis in neutrophils, yet the molecular mechanisms by which neutrophils resist caspase-1-dependent pyroptosis remain unclear. Here, we report that granulocyte-macrophage colony-stimulating factor (GM-CSF) licenses neutrophil pyroptosis upon NLRP3 and Pyrin activation by amplifying TLR4-driven inflammasome priming. Single priming with the TLR1/2 agonist, Pam3CSK4, was also sufficient to license neutrophils to pyroptosis upon NLRP3 and Pyrin activation, as Pam3CSK4 triggered superior inflammasome priming compared to LPS, the prototypic inflammasome priming agent. We further demonstrate that neutrophil pyroptosis requires autocrine TNFR1 signaling and provides genetic evidence that
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Threat assessment shapes neutrophil cell fate upon inflammasome activation. · full record | OpenQuestion